Loading...
BIAF logo

bioAffinity Technologies, Inc.NasdaqCM:BIAF Stock Report

Market Cap US$8.5m
Share Price
US$1.73
My Fair Value
n/a
1Y-79.7%
7D3.6%
1D
Portfolio Value
​
View

bioAffinity Technologies, Inc.

NasdaqCM:BIAF Stock Report

Market Cap: US$8.5m

bioAffinity Technologies (BIAF) Stock Overview

Engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. More details

BIAF fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Earnings have declined by 18.4% per year over past 5 years

Does not have a meaningful market cap ($9M)

Has less than 1 year of cash runway

+ 1 more risk

BIAF Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

bioAffinity Technologies, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for bioAffinity Technologies
Historical stock prices
Current Share PriceUS$1.73
52 Week HighUS$13.80
52 Week LowUS$0.69
Beta-1.33
1 Month Change-12.63%
3 Month Change66.35%
1 Year Change-79.71%
3 Year Change-97.16%
5 Year Changen/a
Change since IPO-99.31%

Recent News & Updates

Recent updates

Analysis Article • Mar 05

Here's Why bioAffinity Technologies (NASDAQ:BIAF) Must Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Sep 28

bioAffinity Technologies receives ~$7.7M from exercise of warrants

bioAffinity Technologies (NASDAQ:BIAF) received ~$7.7M from the exercise of its tradeable and non-tradable warrants issued as part of the Sep. 6 public offering of securities. A total of 725,576 tradeable warrants at $7.35 per share and 310,910 non-tradable warrants at $7.656 per share were exercised. Separately, the company had received ~$7.9M in gross proceeds from the underwritten public offering of 1,282,600 units. The proceeds are intended to be used to expand existing operations, for the commercialization of its CyPath Lung test and regulatory approvals and research and development of additional diagnostics and cancer therapeutics. It may also be used for working capital and general corporate purposes. Shares were trading +52.36% pre-market. Source: Press Release
Seeking Alpha • Sep 14

BioAffinity stock jumps 42% after peer-reviewed data on lung test

Newly IPO’ed biotech BioAffinity Technologies, Inc. (NASDAQ:BIAF) added ~42% in the morning hours Wednesday after the company announced the peer-reviewed publication of data on flow cytometry, a method it uses in its CyPath Lung noninvasive test. As published in the journal PLOS ONE, the research highlights high-throughput flow cytometry analysis of sputum. Results support the use of sputum analysis through flow cytometry as the basis of high-throughput diagnostic tests to evaluate lung health. “In the paper, we describe an innovative and highly efficient method to analyze sputum for the presence of lung cancer, with the potential to focus on other diseases such as COPD and asthma,” BIAF Chief Executive Maria Zannes noted. BIAF went public early this month, raising $7.8M in gross proceeds.

Shareholder Returns

BIAFUS BiotechsUS Market
7D3.6%-3.1%-2.9%
1Y-79.7%26.9%23.5%

Return vs Industry: BIAF underperformed the US Biotechs industry which returned 30.9% over the past year.

Return vs Market: BIAF underperformed the US Market which returned 26.3% over the past year.

Price Volatility

Is BIAF's price volatile compared to industry and market?
BIAF volatility
BIAF Average Weekly Movement40.7%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: BIAF's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: BIAF's weekly volatility has increased from 28% to 40% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201457Maria Zannesbioaffinitytech.com

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

bioAffinity Technologies, Inc. Fundamentals Summary

How do bioAffinity Technologies's earnings and revenue compare to its market cap?
BIAF fundamental statistics
Market capUS$8.52m
Earnings (TTM)-US$15.88m
Revenue (TTM)US$5.66m
1.4x
P/S Ratio
-0.5x
P/E Ratio

Is BIAF overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIAF income statement (TTM)
RevenueUS$5.66m
Cost of RevenueUS$3.79m
Gross ProfitUS$1.87m
Other ExpensesUS$17.75m
Earnings-US$15.88m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-3.50
Gross Margin33.08%
Net Profit Margin-280.57%
Debt/Equity Ratio2.7%

How did BIAF perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/05 22:56
End of Day Share Price 2026/06/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

bioAffinity Technologies, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anthony VendettiMaxim Group